公开(公告)号：US20050215479A1

公开(公告)日：2005-09-29

申请号：US10418953

申请日：2003-04-18

申请人： Richard Boyd ,  Ann Chidgey

发明人： Richard Boyd ,  Ann Chidgey

IPC分类号： A61K38/09 ,  C12Q1/68 ,  G01N33/00 ,  G01N33/74

CPC分类号： G01N33/743

摘要： The present disclosure provides a method for determining whether a patient's immune system can be modified through stimulation of thymus function. In one embodiment, sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. In particular, the level of these factors in the patient's blood stream is observed. In another embodiment, the level of new T cells is monitored. An early response, such as within hours or days of the ablation, indicates that the patient's thymus is disposed to regeneration through sex steroid ablation.

摘要翻译： 本公开提供了一种用于确定患者的免疫系统是否可以通过刺激胸腺功能而被修改的方法。 在一个实施方案中，在患者中消化性类固醇，并监测所产生的胸腺因子。 特别地，观察到患者血液中的这些因素的水平。 在另一个实施方案中，监测新T细胞的水平。 早期反应，如消融后数小时或数天内，表明患者的胸腺通过性类固醇消融进行再生。

公开(公告)号：US20050042679A1

公开(公告)日：2005-02-24

申请号：US10749120

申请日：2003-12-30

申请人： Richard Boyd ,  Ann Chidgey

发明人： Richard Boyd ,  Ann Chidgey

IPC分类号： G01N33/53

CPC分类号： G01N33/6863 ,  G01N33/6869 ,  G01N33/74

摘要： The present disclosure provides a method for determining whether a patient's immune system can be modified through stimulation of thymus function. In one embodiment, sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. In particular, the level of these factors in the patient's blood stream is observed. In another embodiment, the level of new T cells is monitored. An early response, such as within hours or days of the ablation, indicates that the patient's thymus is disposed to regeneration through sex steroid ablation.

公开(公告)号：US20070274946A1

公开(公告)日：2007-11-29

申请号：US10553608

申请日：2004-04-19

申请人： Richard Boyd ,  Gabrielle Goldberg ,  Ann Chidgey ,  Jayne Sutherland

发明人： Richard Boyd ,  Gabrielle Goldberg ,  Ann Chidgey ,  Jayne Sutherland

IPC分类号： A61K48/00 ,  A61K35/12 ,  A61P37/00 ,  A61P41/00 ,  A61K38/20

CPC分类号： A61K38/2046 ,  A01K67/0271 ,  A01K2267/0381 ,  A61K31/277 ,  A61K35/28 ,  A61K38/09 ,  A61K38/13 ,  A61K38/193 ,  A61K39/001 ,  A61K45/06 ,  C12N5/0647 ,  C12N2501/125 ,  C12N2501/235 ,  A61K2300/00

摘要： The present disclosure provides methods for inducing tolerance in a recipient to a mismatched graft of an organ, tissue, and/or cells, by disrupting sex steroid signaling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic regeneration. In some embodiments, sex steroid signaling in the patient, is interrupted or ablated by the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), selective progesterone response modulators (SPRMs), ERDs, aromatase inhibitors, or various combinations thereof.

摘要翻译： 本公开提供了通过破坏患者中的性类固醇信号传导来诱导受体中器官，组织和/或细胞的错配移植物的耐受性的方法，其中改善骨髓和其他免疫细胞功能而不在 ，或同时进行胸腺再生。 在一些实施方案中，通过施用LHRH激动剂，LHRH拮抗剂，抗LHRH受体抗体，抗LHRH疫苗，抗雄激素，抗雌激素，选择性雌激素受体调节剂（SERMs），患者中的性别类固醇信号传导被中断或消融 ），选择性雄激素受体调节剂（SARM），选择性孕酮应答调节剂（SPRM），ERD，芳香酶抑制剂或其各种组合。

公开(公告)号：US20100178700A1

公开(公告)日：2010-07-15

申请号：US12598680

申请日：2008-05-02

申请人： Anne Fletcher ,  Ann Chidgey ,  Natalie Seach ,  Richard Boyd

发明人： Anne Fletcher ,  Ann Chidgey ,  Natalie Seach ,  Richard Boyd

IPC分类号： C12N5/07

CPC分类号： G01N33/56972 ,  A61K35/26 ,  C12N5/065 ,  G01N33/5011 ,  G01N33/5047 ,  G01N2333/70539 ,  G01N2800/52

摘要： The present invention relates generally to novel thymic cellular populations and, more particularly, to novel thymic epithelial cellular populations. Most particular, the present invention is directed to novel thymic epithelial progenitor cell populations. The cellular populations of the present invention are useful in a wide range of clinical and research settings including, inter alia, the in vitro or in vivo generation of thymic epithelial cell populations and the therapeutic or prophylactic treatment of a range of conditions via the administration of these cells. Also facilitated is the design of in vitro based screening systems for testing the therapeutic impact and/or toxicity of potential treatment or culture regimes to which thymic epithelial cells may be exposed. In another aspect, the present invention is directed to a method of identifying thymic epithelial cellular subpopulations and, more particularly, thymic epithelial progenitors by screening for the co-expression of markers including MHC Class II, UEA1 and Ly51. This method is useful in a range of applications including, but not limited to, assessing or monitoring for the presence of thymic epithelial cell populations and/or facilitating the isolation of or enrichment for these cellular populations of use in a range of research and clinical applications.

摘要翻译： 本发明一般涉及新颖的胸腺细胞群体，更具体地涉及新颖的胸腺上皮细胞群体。 最特别地，本发明涉及新颖的胸腺上皮祖细胞群。 本发明的细胞群体在广泛的临床和研究环境中有用，包括特别是体外或体内产生胸腺上皮细胞群体，以及通过施用方法治疗或预防一系列病症的方法 这些细胞。 还促进了用于测试可能暴露胸腺上皮细胞的潜在治疗或培养方案的治疗影响和/或毒性的基于体外的筛选系统的设计。 另一方面，本发明涉及通过筛选包括MHC II类，UEA1和Ly51在内的标志物的共表达来鉴定胸腺上皮细胞亚群，更特别是胸腺上皮祖细胞的方法。 该方法在一系列应用中是有用的，包括但不限于评估或监测胸腺上皮细胞群体的存在和/或促进这些在一系列研究和临床应用中使用的这些细胞群体的分离或富集 。